Pretax income is the income that a company earns before paying income taxes. Leap Therapeutics's pretax income for the
three
months ended in Dec. 2023 was $-12.47 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Dec. 2023 was $-81.41 Mil.
Leap Therapeutics's pretax margin was %.
During the past 12 years, Leap Therapeutics's highest Pretax Margin was -1834.40%. The lowest was -2707.40%. And the median was -2270.90%.
Leap Therapeutics Pre-Tax Income Historical Data
The historical data trend for Leap Therapeutics's Pre-Tax Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Leap Therapeutics's Pre-Tax Income
For the Biotechnology subindustry, Leap Therapeutics's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Leap Therapeutics's Pre-Tax Income Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Leap Therapeutics's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where Leap Therapeutics's Pre-Tax Income falls into.
Leap Therapeutics Pre-Tax Income Calculation
This is the income that a company earns before paying income taxes.
Leap Therapeutics's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as
Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-81.41 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Leap Therapeutics (NAS:LPTX) Pre-Tax Income Explanation
Leap Therapeutics's Pretax Margin for the quarter that ended in Dec. 2023 is calculated as
During the past 12 years, Leap Therapeutics's highest Pretax Margin was -1834.40%. The lowest was -2707.40%. And the median was -2270.90%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Leap Therapeutics Pre-Tax Income Related Terms
Thank you for viewing the detailed overview of Leap Therapeutics's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.
Leap Therapeutics (Leap Therapeutics) Business Description
Leap Therapeutics Inc is a biopharmaceutical company developing novel therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways and by harnessing the immune system to attack cancer cells. Its clinical stage program is DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1. DKK1 is a protein that regulates the Wnt signaling pathways and enables tumor cells to proliferate and spread, as well as suppresses the immune system from attacking the tumor. The company is studying DKN-01 in multiple ongoing clinical trials in patients with esophagogastric cancer, gynecologic cancers, or prostate cancer. Its other clinical studies include P204,and P205.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LPTX has been successfully added to your 